195 related articles for article (PubMed ID: 34767591)
41. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
42. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
43. Loss of ZNF677 Expression Is an Independent Predictor for Distant Metastasis in Middle Eastern Papillary Thyroid Carcinoma Patients.
Siraj AK; Poyil PK; Parvathareddy SK; Alobaisi K; Ahmed SO; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360599
[TBL] [Abstract][Full Text] [Related]
44. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram.
Chen F; Li Z; Deng C; Yan H
J Cell Biochem; 2019 Dec; 120(12):19673-19683. PubMed ID: 31271223
[TBL] [Abstract][Full Text] [Related]
45. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
[TBL] [Abstract][Full Text] [Related]
46. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
[TBL] [Abstract][Full Text] [Related]
48. Tumor promoting effects of glucagon receptor: a promising biomarker of papillary thyroid carcinoma via regulating EMT and P38/ERK pathways.
Jiang HC; Chen XR; Sun HF; Nie YW
Hum Cell; 2020 Jan; 33(1):175-184. PubMed ID: 31782107
[TBL] [Abstract][Full Text] [Related]
49. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of novel long intergenic non‑coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer.
Tan J; Liu L; Zuo Z; Song B; Cai T; Ding D; Lu Y; Ye X
Oncol Rep; 2020 Oct; 44(4):1489-1501. PubMed ID: 32945494
[TBL] [Abstract][Full Text] [Related]
51. Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Hussain AR; Bu R; Ahmed M; Jehan Z; Beg S; Al-Sobhi S; Al-Dayel F; Siraj AK; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2015 Jul; 100(7):E974-85. PubMed ID: 25974735
[TBL] [Abstract][Full Text] [Related]
52. An 8 miRNA-Based Risk Score System for Predicting the Prognosis of Patients With Papillary Thyroid Cancer.
Yi W; Liu J; Qu S; Fan H; Lv Z
Technol Cancer Res Treat; 2020; 19():1533033820965594. PubMed ID: 33054579
[TBL] [Abstract][Full Text] [Related]
53. lncRNA GAS8-AS1 genetic alterations in papillary thyroid carcinoma and their clinical significance.
Zhou DL; Liu Q; Xu BH; Li Y; Su X; Ye ZL; Zhang X; Peng JL; Deng L; Tang T; Shao Q; Ma JJ; Yang XH; He CY
Cancer Biomark; 2020; 29(2):255-264. PubMed ID: 32675393
[TBL] [Abstract][Full Text] [Related]
54. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
[TBL] [Abstract][Full Text] [Related]
55. Role of global aberrant alternative splicing events in papillary thyroid cancer prognosis.
Lin P; He RQ; Huang ZG; Zhang R; Wu HY; Shi L; Li XJ; Li Q; Chen G; Yang H; He Y
Aging (Albany NY); 2019 Apr; 11(7):2082-2097. PubMed ID: 30986203
[TBL] [Abstract][Full Text] [Related]
56. m
Hou J; Shan H; Zhang Y; Fan Y; Wu B
Am J Otolaryngol; 2020; 41(4):102547. PubMed ID: 32474328
[TBL] [Abstract][Full Text] [Related]
57. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
58. Biotinidase is a novel marker for papillary thyroid cancer aggressiveness.
So AK; Kaur J; Kak I; Assi J; MacMillan C; Ralhan R; Walfish PG
PLoS One; 2012; 7(7):e40956. PubMed ID: 22911723
[TBL] [Abstract][Full Text] [Related]
59. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
[TBL] [Abstract][Full Text] [Related]
60. Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma.
Shi J; Wu P; Sheng L; Sun W; Zhang H
Cancer Cell Int; 2021 Dec; 21(1):669. PubMed ID: 34906147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
